Navigation Links
Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
Date:3/13/2008

or the

cohort dosed least frequently.

-- As expected in this short term study, the levels of relevant markers

of Gaucher disease including platelet counts, hemoglobin levels,

glucocerebroside (substrate) levels, chitotriosidase activity and

pulmonary activation-related chemokine (PARC) levels were maintained.

"These data give us great confidence in moving our Gaucher program forward," said John F. Crowley, President and CEO of Amicus Therapeutics. "In addition to a 6-month Phase 2 study in individuals naive to ERT, which is currently underway, we plan to initiate a longer-term study in individuals switching from enzyme replacement therapy to Plicera in the second half of this year."

As of November 2007, Plicera is being developed in partnership with Shire Human Genetic Therapies (HGT), a business unit of Shire plc, which is focused on genetic diseases.

About Gaucher Disease

Gaucher disease is a lysosomal storage disorder caused by inherited genetic mutations in the GBA gene, which result in deficient activity of the enzyme acid beta-glucosidase, also known as glucocerebrosidase (GCase). Deficient GCase activity leads to lysosomal accumulation of glucocerebroside inside certain cells, which is believed to cause the various symptoms of Gaucher disease, including an enlarged liver and spleen, abnormally low levels of red blood cells and platelets and skeletal complications. In some cases there is significant impairment of the central nervous system.

Gaucher disease is estimated to affect approximately 10,000 people in the developed world. The U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for the active ingredient in Plicera in the United States and the European Commission has designated Plicera as an orphan medicinal product in the European Union.

About Amicus Therapeutics

Amicus Therapeutics is a biopharm
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014  ARCH Venture Partners, one ... in the development of seed and early-stage advanced ... fund closed with more than $400 million in ... million subscription target by more than $150 million. ... the strength and potential of our approach to ...
(Date:8/27/2014)... Raton, FL (PRWEB) August 27, 2014 ... are applied through the use of a handheld spray, ... across the United States. , The brand began ... unit. BIOEQUA researchers were surprised to learn that the ... be made extremely small and delivered directly to skin's ...
(Date:8/27/2014)... 27, 2014 Remcom announces an update ... new features for the biomedical industry. The central ... Thermal Sensor, exclusive to the Bio-Pro version of the ... XFdtd, developed to calculate the biological effects of electromagnetic ... added to all versions to expand engineers’ post-processing options. ...
(Date:8/26/2014)... they believe is the thinnest-possible semiconductor, a new ... three atoms thick. , The University of Washington ... semiconductor materials can be connected in an atomically ... could be the basis for next-generation flexible and ... solar technologies. , "Heterojunctions are fundamental elements of ...
Breaking Biology Technology:Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3BIOEQUA'S EQUA ESSENTIAL Product Line Redefines Skin Care & Now Available in America 2Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 2Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 3Scientists craft atomically seamless, thinnest-possible semiconductor junctions 2
... at the University of Copenhagen has been chosen to ... Programme. The 2.5 million appropriation will aim to ... and the Nano-Science Center is the first Danish research ... Seventh Programme. , The goal of the research project ...
... - DuPont today congratulated,growers planting Pioneer(R) brand sorghum ... categories in the 2007 National Sorghum Producers, (NSP),Yield ... with Pioneer sorghum,hybrid 84G62., Farmers growing Pioneer ... contest segments. First-, second- and third-place national,honors were ...
... Diagnostics,Incorporated (NYSE: DGX ), the nation,s leading ... that its Board of,Directors declared a quarterly cash ... share, payable on January 23, 2008, to shareholders ... Diagnostics, Quest Diagnostics is the leading provider ...
Cached Biology Technology:DuPont Congratulates Growers Planting Pioneer(R) Brand Sorghum Hybrids in Winning Majority of National Categories in Yield Contest 2Quest Diagnostics Declares Quarterly Cash Dividend 2
(Date:8/27/2014)... greatest risk to Europe based upon a proxy for ... using a ,big data, approach to scientific research. , ... Global Health ranked the top 100 pathogens affecting humans ... system which, they believe, will help governments across the ... infectious diseases, including as a result of climate change, ...
(Date:8/27/2014)... exists as five strains, none of which have approved ... Sudan ebolavirus (SUDV). Although not the strain currently devastating ... recently as 2012. In a new study appearing in ... report a possible therapy that could someday help treat ... Jonathan Lai and colleagues explain that about 50-90 percent ...
(Date:8/27/2014)... health advocates, campaigns against trans-fats have largely succeeded ... taking aim at sugar for its potential contributions ... are still wrangling over the best way to ... an article in Chemical & Engineering News ... American Chemical Society. , In the article, Stephen ...
Breaking Biology News(10 mins):Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks 2
... is giving the VIP treatment to laboratory mice in ... , VIP is not "very important person," but vasoactive ... gut, that is also made by a specialized group ... Washington University assistant professor of Biology in Arts & ...
... Opening the door to a new way of understanding ... group of researchers at Scripps Institution of Oceanography at ... groundbreaking analysis of the North Pacific Ocean and how ... study, published in the May 19 issue of the ...
... Biocenter, University of Helsinki, show that atomic structures can ... as fossils did for the dinosaurs and reptiles. Their ... Molecular Cell. , These "molecular fossils" also revealed ... same structure. One plausible explanation may be that viral ...
Cached Biology News:Discovery clarifies role of peptide in biological clock 2Scripps scientists find potential for catastrophic shifts in Pacific ecosystems 2Scripps scientists find potential for catastrophic shifts in Pacific ecosystems 3
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
... designer enzyme that enables RT-PCR in ... enzyme allows reverse transcription and PCR ... temperatures (65C), which helps to remove ... results in highly stringent, accurate annealing ...
... Lyophilized solid. Highly active enzyme useful ... of target substrates, and inhibitor screening. Specific ... is defined as the amount of enzyme that will ... hour at 37 C at saturated substrate concentrations. ...
Request Info...
Biology Products: